BranchLab Raises $26 Million In Series A Financing For Its AI Platform To Commercialize Pharmaceuticals

BranchLab, an artificial intelligence (AI) platform for pharmaceutical commercialization, has raised $26 million in a Series A financing round led by McKesson Ventures, with participation from FCA Venture Partners, Sanofi Ventures, and AIX Ventures. The round brings the company's total funding to $35 million.

Pharmaceutical commercialization—which encompasses consumer identification, audience segmentation, activation, and real-world measurement—has historically depended on fragmented vendors, delayed analytics, and manual workflows. The result is a process that is data-rich but slow to act on, limiting how quickly teams can learn, adapt, and respond.

BranchLab's platform is designed to address this . . .